We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+11.62%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.87B
AUM Growth
+$212M
(+13%)
Cap. Flow
+$49.5M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
45.13%
Holding
78
New
31
Increased
13
Reduced
11
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$75M |
| 2 |
AGN
Allergan plc
AGN
|
+$50M |
| 3 |
AGN
Allergan Inc
AGN
|
+$48.9M |
| 4 |
AbbVie
ABBV
|
+$46.5M |
| 5 |
BEAM
BEAM INC COM STK (DE)
BEAM
|
+$46.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$64.6M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$62M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$58.8M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$51.5M |
| 5 |
CFN
CAREFUSION CORPORATION
CFN
|
+$49.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.15% |
| 2 | Financials | 6.73% |
| 3 | Consumer Staples | 6.5% |
| 4 | Materials | 1.82% |
| 5 | Real Estate | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
| $164M | 8.77% |
11,000,000
-3,900,000
| -26% | -$58.8M |
|
2
Gilead Sciences
GILD
$163B
| $94.3M | 5.05% |
1,500,000
-600,000
| -29% | -$35.9M |
|
|
ARTC
3
DELISTED
ARTHROCARE CORP
ARTC
| $81.8M | 4.39% |
2,300,000
+50,000
| +2% | +$1.75M |
|
4
Intuitive Surgical
ISRG
$126B
| $80.7M | 4.33% |
1,930,986
+265,986
| +16% | +$11.7M |
|
|
5
PUT
Gilead Sciences
GILD
$163B
| $78.7M | 4.22% |
+1,251,500
| New | +$74.8M |
|
|
WMGI
6
DELISTED
Wright Medical Group Inc
WMGI
| $78.2M | 4.19% |
3,000,000
+225,000
| +8% | +$5.87M |
|
|
7
Zimmer Biomet
ZBH
$18.4B
| $76M | 4.07% |
+952,750
| New | +$75M |
|
8
eHealth
EHTH
$43.8M
| $72.7M | 3.89% |
2,252,119
| – | – |
|
|
CBST
9
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $58.8M | 3.15% |
925,000
-275,000
| -23% | -$16.6M |
|
|
CBST
10
PUT
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $57.2M | 3.07% |
+900,000
| New | +$54.4M |
|
|
AGN
11
DELISTED
Allergan plc
AGN
| $54M | 2.89% |
+375,000
| New | +$50M |
|
|
AGN
12
DELISTED
Allergan Inc
AGN
| $49.3M | 2.64% |
+545,000
| New | +$48.9M |
|
|
13
AbbVie
ABBV
$455B
| $47M | 2.52% |
+1,050,000
| New | +$46.5M |
|
|
BEAM
14
DELISTED
BEAM INC COM STK (DE)
BEAM
| $46.9M | 2.51% |
+725,000
| New | +$46.5M |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
| $46.5M | 2.49% |
400,000
-250,000
| -38% | -$27.4M |
|
16
Viatris
VTRS
$20.7B
| $45.8M | 2.46% |
1,200,000
-925,000
| -44% | -$32.6M |
|
|
WWAV
17
DELISTED
The WhiteWave Foods Company
WWAV
| $45.4M | 2.44% |
2,275,000
+1,244,034
| +121% | +$23.6M |
|
|
AET
18
DELISTED
Aetna Inc
AET
| $44.8M | 2.4% |
+700,000
| New | +$44.9M |
|
19
Molina Healthcare
MOH
$10.2B
| $39.2M | 2.1% |
1,100,000
+375,000
| +52% | +$13.8M |
|
20
Agilent Technologies
A
$39.2B
| $38.4M | 2.06% |
+1,048,500
| New | +$35.3M |
|
|
AEGR
21
DELISTED
Aegerion Pharmaceuticals
AEGR
| $36.4M | 1.95% |
425,000
+298,300
| +235% | +$25.3M |
|
22
Tenet Healthcare
THC
$21.8B
| $35M | 1.88% |
850,000
-150,000
| -15% | -$6.27M |
|
23
Edwards Lifesciences
EW
$50B
| $34.8M | 1.87% |
+3,000,000
| New | +$35.1M |
|
|
MON
24
DELISTED
Monsanto Co
MON
| $33.9M | 1.82% |
+325,000
| New | +$32.7M |
|
25
Innoviva
INVA
$1.57B
| $28.6M | 1.53% |
868,700
+591,088
| +213% | +$18.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2013 Portfolio in Review
As of Q3 2013, HealthCor Management held 78 positions worth $1.87B, up 13% from $1.65B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
HealthCor Management's Q3 2013 filing shows 31 new, 13 increased, 11 reduced and 20 closed positions. Its largest new stake was Zimmer Biomet: 952,750 shares worth $76M. The largest sale was Biogen, an estimated $64.6M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 71% a quarter earlier, followed by Financials and Consumer Staples.
- HealthCor Management's largest Q3 2013 buy was Zimmer Biomet: 952,750 shares worth $76M.
- HealthCor Management added most to Aegerion Pharmaceuticals in Q3 2013, an estimated $25.3M increase.
- HealthCor Management's biggest Q3 2013 reduction was Veradigm Inc. Common Stock, cutting an estimated $58.8M.
- HealthCor Management fully exited Biogen in Q3 2013, selling an estimated $64.6M.
- HealthCor Management's ten largest holdings make up 45% of its $1.87B portfolio in Q3 2013.
- HealthCor Management opened 31 new positions and closed 20 in Q3 2013.
- HealthCor Management's portfolio value rose 13% quarter-over-quarter to $1.87B.
Based on HealthCor Management's 13F filing for Q3 2013, filed 14 Nov 2013.